Chromocell Therapeutics Corp. announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler. The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications.

Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae. Chronic eye pain indications include autoimmune diseases, dry eye and neuropathic etiologies. Chromocell?s platform uniquely targets the NaV1.7 channels on the cornea with the ability to treat all eye pain indications.